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l - : - tñ Sulfonylurea (SU) derivatives exert their hypoglycemic ef­
fect by blockade of adenosine-S'-triphosphate-sensitive 
potassium (KATP) channels in the beta cell of the pancreas. Inter­
estingly, Katp channels also occur in the cardiovascular system, 
where they are thought to play an important role in cardiopro­
tective mechanisms against ischemia. We have recently shown 
that the classical second generation SU-derivative gllbenclamide 
is able to block vascular KATP channels in man, whereas the newly 
developed second generation derivative glimepiride was devoid 
of this property. The aim of this study was to determine whether 
the first generation SU derivative tolbutamide has KATP channel 
blocking properties in humans. In a group of 12 healthy male 
non-smoking volunteers, w e investigated whether therapeutic 
concentrations of tolbutamide were able to inhibit the forearm 
vasodilation in response to  the infusion of the KATP channel open­
ing drug diazoxide into the brachial artery. Changes in forearm 
blood flow were recorded by venous occlusion mercury-in-silastic 
strain-gauge plethysmography. Diazoxide alone increased the 
forearm blood flow ratio dose-dependently by ultimately 691 ± 
198%. A second diazoxide infusion in the presence of tolbu­
tamide revealed a comparable vasodilator response with a per­
centage increase in forearm blood flow ratio of ultimately 542 ± 
111 %. This response did not differ from the vasodilator response 
to diazoxide alone. The present study shows that therapeutic 
concentrations of tolbutamide are not able to attenuate the va­
sodilation caused by the KATP channel opener diazoxide in man. 
When compared with published data on second generation SU- 
derivatives, tolbutamide shows an intermediate position be­
tween glibenclamide (with significant blockade of vascular KATP 
channels) versus glimepiride (with no blockade at all). It remains 
to be determined whether these acute effects of SU derivatives 
on pharmacological opening of forearm vascular KATP channels 
can be extrapolated to  the chronic effects of these drugs on 
ischemia-mediated opening of myocardial KATP channels during 
treatment of NIDDM patients.
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Introduction
Since the introduction of sulfonylurea (SU) derivatives, studies 
of these agents have been focused on metabolic effects in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) (11,17). Both the first generation SU derivative tolbu­
tamide and the second generation SU derivative glibenclamide 
induce their pharmacological effect by blockade of adenosine- 
5'-triphosphate-sensitive potassium (KATP) channels in the beta 
cell of the pancreas. This ultimately promotes an influx of cal­
cium with subsequent stimulation of insulin release (9). In the 
last two decades, an increasing interest in the extra-pancreatic 
effects of these drugs has been reported (1,3,19,21,22,24). In 
animal models, SU derivatives have been shown to attenuate 
the vasodilator response to an ischemic stimulus (2), and to 
abolish the protective effects of myocardial ischemic precon­
ditioning (12,26). In these preparations, glibenclamide has 
even been shown to increase myocardial infarct size (25). In 
theory, the aforementioned observations may suggest harmful 
cardiovascular effects of SU derivatives when used under con­
ditions of ischemia in patients with NIDDM. In 1970 the Uni­
versity Group Diabetes Program (UGDP) study first reported 
possible adverse cardiovascular effects of SU derivatives in 
man (27). Although this study has been extensively criticized, 
recent observations on the interaction between SU-derivatives 
and human vascular I<ATP-channels may be of great importance 
with respect to this issue (5).
We have just shown that the classical second generation SU 
derivative glibenclamide can interact with vascular I<ATP chan­
nels in man at therapeutic concentrations (5). In theory, this 
interaction may have contributed to the cardiovascular adverse 
effects as reported in the UGDP-study (5). However, it has to 
be emphasized that tolbutamide and not glibenclamide was 
used in the UGDP-study. Almost all experimental animal stu­
dies on cardiovascular effects of SU-derivatives have used 
glibenclamide, and not tolbutamide. Therefore, we conducted
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a study to evaluate whether therapeutic concentrations of 
tolbutamide are able to block vascular KATP-channels in 
humans. This question was investigated by recording the in­
teraction of tolbutamide with the KATP-channel opening drug 
diazoxide. The data will be discussed in relation to previously 
published original observations on glibenclamide (5). Data on 
the newly developed second generation SU-derivative 
glimepiride wil also be discussed, since this agent seems to be 
devoid of I<ATP-channei blocking properties (5,14,15).
Methods
This study investigated the putative inhibitoiy effects of tolbu­
tamide on the Katp channel-mediated vasodilation by di­
azoxide. To address this issue, the perfused forearm technique 
was used (28). The study protocol was approved by the local 
ethics committee, and all 12 participants gave written in­
formed consent before entering the study. All experiments 
were performed in healthy male non-smoking volunteers with 
a normal history, physical examination, and blood pressure. 
The characteristics of the volunteers are listed in Table 1. Each 
volunteer participated in only one experiment and was in­
structed to abstain from caffeine-containing beverages and al­
cohol at least 24 hours before the experiment. Furthermore, 
they were asked to eat a light meal two hours before the ex­
periment was started and then to abstain from further food 
intake until after the experiment Forearm volume was 
measured by water displacement. The experiments were per­
formed with the subjects in the supine position in a quiet 
temperature controlled room (22 °C), to ensure that forearm 
blood flow (FBF) predominantly reflected forearm muscle per­
fusion (8).
Table 1 Characteristics of the healthy volunteers.
n 12
Age (year) 26 ± 7
Weight (kg) 76 ±13
Height (m) 1.84±0.06
Body mass index (kg/m2) 22 ±3
Systolic blood pressure (mmHg)* 123 ±6
Diastolic blood pressure (mmHg)* 65 ±7
Heart rate (bpm) 62 ±6
Data are presented as means (± SD).
*Sphygmomanometrically obtained blood pressure after 5 min supine rest
The effects of tolbutamide on the dia2oxide-mediated vasodi­
lation were studied. A cannula was inserted into the brachial 
artery (Angiocath, 20 gauge, Deseret Medical Inc., Becton Dick­
inson and Comp., Sandy, Utah). Antecubital veins of the left and 
the right arm were also cannulated. After an equilibration pe­
riod of 45 minutes, a 35 minute intraarterial infusion of placebo 
(saline) was started. After 10 minutes of saline infusion, base­
line measurements of blood pressure, heart rate, and bilateral 
FBF were taken during the concomitant intraarterial infusion 
of placebo. Then*a dose-response curve of the vasodilator ef­
fects of diazoxide was made (three intraarterial dosages: 0.25, 
0.75, 2.25 mg/min/dl using an automated syringe infusion 
pump) (type STC-521, Terumo Corp., Tokyo, Japan). Blood pres­
sure was measured via the intraarterial line using a Hewlett 
Packard monitor (type 7853B, Hewlett Packard GmbH, Böblin­
gen, Germany). Forearm blood flow was measured by ECG-trig- 
gered venous occlusion mercury-in-silastic strain-gauge
plethysmography (Hokanson EC4, D.E. Hokanson, Inc., Iss- 
aquah, Washington, USA). During all recordings of the FBF, the 
hand circulation was completely occluded by a wrist cuff in­
flated 100 mmHg above the systolic blood pressure to be sure 
that measurements only referred to the forearm skeletal 
muscle vascular bed (16). After a subsequent equilibration of 
60 minutes to allow parameters to return towards baseline 
levels, baseline values were again recorded during concomi­
tant intraarterial infusion of placebo. Then a second dose-re­
sponse curve was made in all subjects, but now with concom­
itant intraarterial infusion of tolbutamide instead of placebo 
(tolbutamide dose 1.0 mg/min/dl).
Venous blood samples from the non-experimental arm were 
taken for the determination of insulin and C-peptide as well as 
for tolbutamide concentrations, both before and at the end of 
tolbutamide infusion. After each diazoxide infusion, venous 
blood samples from the experimental side were taken for the 
determination of local tolbutamide concentrations. At all these 
time points, the plasma glucose concentration was also 
measured. Glucose was measured immediately by an Ac- 
cutrend glucose analyzer (type 1284851, Boehringer, Mann­
heim, Germany). Because of the long half-life, high protein 
binding (7,23) and possible incorporation of SU derivatives in 
the plasma membrane (20), randomization of placebo and 
tolbutamide was not possible because of carry-over effects.
For comparison, we also discuss here the data from identical 
studies with glibenclamide, which was given in a dose of 0.33 
jxg/min/dl, and from studies with the newly developed SU 
derivative glimepiride, administered in a relatively high dose 
of 2.5 |ag/min/dl (5).
Humoral parameters
For determinations of local serum concentrations of the SU 
derivative, venous blood samples were collected in glass tubes 
without additives. After 20 minutes the blood was centrifuged 
at 3000 rpm for 10 minutes. Then serum was frozen at - 2 0 DC. 
The drug concentrations in these serum samples were deter­
mined at the laboratories of Hoechst Marion Roussel, Frankfurt, 
Germany.
Insulin and C-peptide were measured in venous blood samples 
collected in chilled glass tubes coated with lithium-heparin. 
The blood was centrifuged at 3000 rpm for 10 minutes. Then 
plasma was frozen at -20"G In these samples, insulin and C- 
peptide were determined in our laboratories using specific 
RIAs. C-Peptide was measured with a standard kit (D.P.C, Los 
Angeles, CA, USA) and insulin with a procedure using standard 
and tracer prepared from monocomponent human insulin 
(NOVO, Zoeterwoude, The Netherlands).
Calculations and statistics
Forearm vascular resistance (FVR) was calculated as the 
quotient of mean arterial pressure (MAP) and FBF. The ratio of 
experimental to non-experimental FBF was calculated to cor­
rect for systemic changes due to time or arousal in order to 
refer only to changes induced by local infusions (10). For each 
dose of diazoxide, FBF values in the las t two minutes of infusion 
were averaged to one mean representative value. Likewise, ab­
solute and percentage changes from baseline were calculated.
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Table 2 Mean (±SE) baseline 
values of forearm blood flow 
and vascular resistance, and the 
absolute and percentage 
changes of these parameters 
induced by diazoxide infusion, 
both during concomitant 
placebo (upper part) or tol­
butamide infusion (lower part). 
AU: Arbitrary Units
Baseline 2 (placebo) 
Baseline 3 (tolbutamide)
3.8±0.5 (ml/min/dl) 
3.1 +0 .4  (ml/min/dl)
27.2 +2.5 (AU) 
36,4±4.7 (AU)
Changes from Baseline (ml/min/dl) (%) (AU) (%)
Diazoxide 0.25 (tolbutamide) 
Diazoxide 0.75 (tolbutamide) 
Diazoxide 2.25 (tolbutamide)
1.8 ±0 .4  
4.3 ±0.9 
12.7 ± 1.8
61 ±14 
146 + 33 
451 ±80
-12 .9  ±3.3 
-19.1 ±3,7 
-27 .8  ±4.7
•34.4 + 6.7 
• 52.6 ±6.8 
■78.5 ±3.0
P-value from ANOVA with repeated 
measures over all diazoxide dosages
0.71 0.76
Forearm Blood FLow Forearm Vascular Resistance
Baseline 1 (placebo) 2.5±0.3 (ml/min/dl) 41.2+4.8 (AU)
Changes from Baseline (ml/min/dl) (%) (AU) (%)
Diazoxide 0,25 (placebo) 2.2 ±0.5 99 ±24 -19.1 ±4.3 -4 2 .4  ±6.7
Diazoxide 0.75 (placebo) 4.0 ±0.7 177 ±34 -24 .2  ±5.4  -54 .3  + 8.4
Diazoxide 2.25 (placebo) 10.4±2.1 457 + 119 -2 9 .7 ± 5 .8  -71.1 ±7.2
In the same manner, values for FVR and FBF-ratio were ob­
tained. The results were analyzed statistically by an analysis of 
variance (ANOVA) with repeated measures over all vasodilator 
dosages. A p-value of < 0.05 was considered statistically signif­
icant. Because of significant differences in baseline values, this 
analysis was performed on the percentage changes from base­
line for the FBF-ratio, but also for the FBF and FVR, followed 
by post-hoc t-tests when ANOVA was significant. Values pre­
sented are means ±SE unless indicated otherwise-
Results
Effects of sulfonylurea derivatives on vasodilator responses
During concomitant placebo infusion, the three dosages of di­
azoxide increased the FBF at the experimental arm dose-de- 
pendently by 99 ±24, 178 ±34 and 457 + 119% respectively. 
Changes at the contralateral arm were negligible: -4±4, -13 
±5 and -  23+5 % respectively. After equilibration, FBF returned 
to baseline levels, and the subsequent infusion in the presence 
of tolbutamide increased FBF by 61 ±14, 146+33 and 451 + 
SO% respectively. This second dose response curve was not 
different from the first one. Table 2 shows the absolute changes 
in FBF as well as in FVR for all dose steps. Fig.l illustrates the 
changes in FBF-ratio induced by diazoxide infusion into the 
brachial artery, both in the presence of placebo or tolbutamide. 
The right panel of this figure shows the percentage changes in 
the FBF-ratio during placebo and tolbutamide, and statistical 
analysis of these data did not reveal a significant difference,
Changes in humoral parameters
Table 3 shows the concentrations of glucose, insulin and C-pep- 
tide throughout the study. As a result of the regional infusion 
and the relatively low cumulative dose of tolbutamide, no in­
crease in systemic insulin or C-peptide concentrations and no 
fall in plasma glucose levels were observed during this study.
During the second dose response curve, tolbutamide concen­
trations were sampled at the end of each diazoxide dose. These
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Fig. 1 The left panel shows the mean (±SE) FBF-ratio at baseline and 
during ¡ntraarterial infusion of the three diazoxide dosages (0.25-
0.75-2.25) with concomitant intraarterial infusion of placebo (closed 
symbols/solid lines), or with concomitant intraarterial infusion of tol­
butamide (open symbols/dashed line). The right panel shows the corre­
sponding mean (±SE) percentage changes from baseline in FBF-ratio. 
The p-vaiue refers to ANOVA with repeated measures over the 
complete dose response curves.
Table 3 Mean (± SE) plasma concentrations of insulin, C-peptide and 
glucose at different time points throughout the study period,
Insulin
(mU/l)
C-peptide
(nmol/l)
glucose
(mmol/l)
Time after cannulatlon
(minutes)
45 18.1 ±4.0 0.76 ±0.14 5.0 ±0.2
80 8.5 ±1.3 0.54± 0.08 5.0 ±0.1
140 12.8 + 1.8 0.57 ±0.08 5.2 ±0.1
170 11.0 ± 2.1 0.53 ±0.08 5.0 ±0.2
180 4.9 ±0.2
185 6.9 ±1.1 0.45 ±0.07 5.1 ±0.1
local serum tolbutamide concentrations averaged 26±4[ig/ml, 
17+2 f.tg/ml and 11 ±1 ¡ig/ml respectively (n « 12). At the end 
of the experiment the systemic tolbutamide concentration had 
accumulated to 5 ±0 jig/ml.
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Discussion
The present study shows that the First generation SU derivative 
tolbutamide does not significantly attenuate the vasodilator 
response to the KATP channel opener diazoxide in man. The in­
traarterial dosages of tolbutamide resulted in local concentra­
tions which were well within the therapeutic range as they 
occur systemically during regular treatment of NIDDM (18). 
These observations argue against a significant effect of tolbu­
tamide treatment on vascular KATP channels in humans.
In theory, the present observations may have been confounded 
by time effects. However, in our previous study on this issue 
we carefully performed time control studies, which showed 
that the repeat of diazoxide infusion in the time frame used in 
the current study resulted in an identical forearm vasodilator 
response (5).
When the effect of tolbutamide on the three vasodilator 
dosages to diazoxide is averaged to one mean value, a simple 
comparison can be made with the previously published data 
on glibenclamide and glimepiride (5). For the sake of compari­
son, these data are depicted in Fig. 2. All these experiments 
have been performed in exactly the same way, and they all 
refer to groups of 12 volunteers. From this figure it is clear that 
tolbutamide has an intermediate position between gliben­
clamide and glimepiride. For glibenclamide the blockade of 
vascular KA1P channels was statistically signifiant (5), whereas 
glimepiride showed no blockade at all.
Mean shift in % response 
100
0
■100
- 200 -
Tolbutamide Glibenclamide
Glimepiride
Fig. 2 When the reduction in diazoxide-induced vasodilation by tolbu­
tamide is averaged for all three diazoxide dose, a mean shift can be 
calculated. This mean shift is depicted in this figure, and compared to 
similar data from a previous study on glibenclamide and glimepiride 
(see reference 5).
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The relative absence of an interaction with vascular I<ATI> chan­
nels by tolbutamide can easily be explained by its weak phar­
macological effect, which also holds for the insulinotropic ef­
fect of this drug. As soon as metabolic regulation of NIDDM is 
insufficient with tolbutamide, the switch to a second genera­
tion SU-derivative is indicated. In this regard it is interesting 
that a switch to glimepiride will clearly improve metabolic reg­
ulation, whereas the function of the vascular I<AXP channels will 
not be impaired by this agent.
Patients with NIDDM are relatively often exposed to myocar- 
dila ischemia. Blockade of vascular I<ATP channels by gliben­
clamide has been shown to impair I<ATP channel-mediated pro­
tective effects (6,12). The UGDP-study suggested that tolbu­
tamide may have adverse cardiovascular effects (27). This has 
also been suggested for glibenclamide (13,24). Our present 
study suggests that after acute administration, tolbutamide 
will probably not attenuate KATP channel mediated cardiopro­
tective mechanisms. However, we can not exclude the possi­
bility that chronic exposure to tolbutamide, such as occurs 
during the treatment of NIDDM, may result in significant 
blockade of vascular KATP channels in man. The present study 
must be interpreted as a call for further studies on the effects 
of chronic treatment with SU-derivatives on 1<ATP channel-me­
diated effects in patients with NIDDM.
Conclusions
We conclude that therapeutic concentrations of the first 
generation SU derivative tolbutamide are not able to attenuate 
vascular I<ATP channels in humans.
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